<DOC>
	<DOCNO>NCT01758042</DOCNO>
	<brief_summary>The main purpose study examine outcome combine bone marrow kidney transplant partially match relate ( haploidentical `` haplo '' ) donor . This pilot study , ask participate blood disorder kidney disease . The aim combine transplant treat underlie blood disorder kidney disease . We expect 10 people participate study . Additionally , person donate kidney also donate bone marrow , may small chance kidney rejection less need long-term use anti-rejection drug . Traditionally , strong cancer treatment drug ( chemotherapy ) radiation use prepare subject 's body bone marrow transplant . This associated high risk serious complication , even subject without kidney disease . This therapy toxic liver , lung , mucous membrane , intestine . Additionally , believe standard therapy may associate high risk complication call graft versus host disease ( GVHD ) new donor cell attack recipient 's normal body . Recently , less intense chemotherapy radiation regimens employ ( call reduce intensity regimen ) cause less injury GVHD patient , thus , allow old less healthy patient undergo bone marrow transplant . In study , reduce intensity regimen chemotherapy radiation use intent produce few toxicity standard therapy . Typical therapy follow standard kidney transplant include multiple lifelong medication aim prevent recipient 's body attack reject donate kidney . These call immunosuppressant drug work `` quiet '' recipient 's immune system allow donate kidney function properly . One goal study decrease duration need immunosuppressant drug follow kidney transplant bone marrow transplant provide donor 's immune system attack donor kidney .</brief_summary>
	<brief_title>Bone Marrow Kidney Transplant Patients With Chronic Kidney Disease Blood Disorders</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<criteria>Patients age 1870 Underlying hematological disorder potentially curable allogeneic bone marrow transplantation . This include , limited : acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , chronic myelogenous leukemia ( CML ) , chronic lymphocytic leukemia ( CLL ) , nonHodgkin lymphoma ( NHL ) , Hodgkin lymphoma , multiple myeloma ( MM ) , myelodysplastic syndrome ( MDS ) , AL amyloidosis , diamond blackfan anemia , myelofibrosis myeloproliferative disease , sickle cell anemia , thalassemia . Existence haploidentical first degree relative pass standard donor evaluation bone marrow kidney donation LVEF &gt; 40 % measure echocardiography MUGA FEV1 , FVC , DLCO &gt; 50 % predict measured standard PFTs Total bilirubin &lt; 2.0 ( unless diagnosis Gilbert 's hemolysis make ) AST , ALT , alkaline phosphatase &lt; 5x institution upper limit normal ABO compatibility host vs. graft direction Men woman reproductive potential must agree use reliable method birth control treatment , woman period 1 year follow transplant . Participants dialysis estimate measure CrCl &lt; 35 ml/min Life expectancy great six month . Recipient ability understand provide inform consent Active serious infection Participation investigational drug use time enrollment Contraindication therapy one propose agent ( e.g. , history allergy rabbit serum ATG ) Serologic positivity HIV , HCV , HbsAg positivity ABO blood group incompatibility hostvsgraft direction Active serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>CKD</keyword>
	<keyword>Bone Marrow</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>BMT</keyword>
	<keyword>Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>CLL</keyword>
	<keyword>MM</keyword>
	<keyword>NHL</keyword>
	<keyword>MDS</keyword>
</DOC>